Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020 Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020
View original post here:
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Orphazyme A/SCompany announcement No. 53/2020 Company Registration No. 32266355
Continue reading here:
New incentive program for the Board of Directors of Orphazyme
Resource hub streamlines and simplifies application process for clinical trials within EU Resource hub streamlines and simplifies application process for clinical trials within EU
Visit link:
Parexel Announces Solution for EU Clinical Trials Information System Regulation
VANCOUVER, Sept. 23, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced that it has filed a Form 211 application with the Financial Industry Regulatory Authority (“FINRA”) to request permission to quote and resume trading of its securities on OTC Markets.
See the original post here:
BetterLife Provides Update on OTC Trading Activity
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials
Read more:
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020.
Go here to see the original:
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress
MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.
See original here:
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair
- Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease
Go here to see the original:
Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research &...
Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies
BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000.
Read the original post:
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids